| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Anita Grigoriadis | Q42396329 |
| Sophia N. Karagiannis | Q40726155 | ||
| James Opzoomer | Q58664750 | ||
| Matthew Fittall | Q58664760 | ||
| James Spicer | Q86599148 | ||
| P2093 | author name string | Debra H Josephs | |
| Heather J Bax | |||
| Silvana Canevari | |||
| Andrew N Tutt | |||
| Mariangela Figini | |||
| Kristina M Ilieva | |||
| Anthony Cheung | |||
| Giulia Pellizzari | |||
| Jacinta Bloomfield | |||
| P2860 | cites work | Interaction of folate receptor with signaling molecules lyn and G(alpha)(i-3) in detergent-resistant complexes from the ovary carcinoma cell line IGROV1 | Q22011053 |
| Nuclear localization of folate receptor alpha: a new role as a transcription factor | Q24306228 | ||
| A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer | Q26781856 | ||
| Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review | Q26828581 | ||
| Serine, glycine and one-carbon units: cancer metabolism in full circle | Q26828610 | ||
| Farletuzumab in lung cancer | Q26997008 | ||
| New perspectives on targeted therapy in ovarian cancer | Q28082524 | ||
| The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? | Q28295141 | ||
| The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity | Q29547693 | ||
| The alpha folate receptor is highly activated in malignant pleural mesothelioma | Q31928563 | ||
| Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection. | Q32097568 | ||
| Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma | Q33179143 | ||
| Tumor detection using folate receptor-targeted imaging agents | Q33340330 | ||
| Functional folate receptor alpha is elevated in the blood of ovarian cancer patients | Q33484181 | ||
| The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy | Q33658554 | ||
| Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors | Q33923397 | ||
| Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer | Q34058510 | ||
| In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB) | Q34073529 | ||
| Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha | Q34111744 | ||
| EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers. | Q34154736 | ||
| Synthesis and biological evaluation of EC20: a new folate-derived, (99m)Tc-based radiopharmaceutical | Q34159853 | ||
| Mechanisms of membrane transport of folates into cells and across epithelia | Q34184787 | ||
| Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. | Q34187879 | ||
| Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications | Q34291624 | ||
| Folate receptors targeted to clathrin-coated pits cannot regulate vitamin uptake | Q34382612 | ||
| Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay | Q34399808 | ||
| Overexpression of folate binding protein in ovarian cancers. | Q34424458 | ||
| BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors | Q34476951 | ||
| Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects. | Q34519790 | ||
| Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors. | Q34778902 | ||
| Folate-targeted therapeutic and imaging agents for cancer | Q34979480 | ||
| Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. | Q41498121 | ||
| Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor. | Q42163046 | ||
| The absence of caveolin-1 increases proliferation and anchorage- independent growth by a Rac-dependent, Erk-independent mechanism. | Q42546542 | ||
| Correction: Folate receptor-α (FOLR1) expression and function in triple negative tumors. | Q42579908 | ||
| Directed therapy of subtypes of triple-negative breast cancer | Q42783788 | ||
| Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study | Q42882546 | ||
| Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody | Q43411971 | ||
| Clinical significance of folate receptor β-expressing tumor-associated macrophages in pancreatic cancer | Q43535475 | ||
| Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p. | Q43560570 | ||
| Synthesis and evaluation of taxol-folic acid conjugates as targeted antineoplastics | Q43976151 | ||
| Glycosyl-phosphatidylinositol-anchored membrane proteins | Q44400636 | ||
| Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results | Q44431019 | ||
| Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. | Q44459409 | ||
| Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting. | Q44463016 | ||
| Use of combination of monoclonal antibodies directed against three distinct epitopes of a tumor-associated antigen: analysis of cell binding and internalization | Q44974769 | ||
| A phase I study of folate immune therapy (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) in patients with renal cell carcinoma | Q45343606 | ||
| The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer | Q45410754 | ||
| Releasing the Brakes on Cancer Immunotherapy. | Q45976317 | ||
| Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy. | Q46028084 | ||
| Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor beta | Q46111695 | ||
| A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages | Q46294712 | ||
| Folate receptor α associated with triple-negative breast cancer and poor prognosis | Q46471016 | ||
| Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers. | Q46818493 | ||
| Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. | Q52833032 | ||
| Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. | Q53358319 | ||
| Phase I clinical trial of 99mTc-etarfolatide, an imaging agent for folate receptor in healthy Japanese adults. | Q53396871 | ||
| Folate receptor overexpression is associated with poor outcome in breast cancer. | Q53554648 | ||
| Folic acid mediates activation of the pro-oncogene STAT3 via the Folate Receptor alpha. | Q53555425 | ||
| New Strategies in Breast Cancer: Immunotherapy. | Q54215651 | ||
| Tumour-associated macrophage polarisation and re-education with immunotherapy | Q38305200 | ||
| Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications | Q38309549 | ||
| Folate receptor in adenocarcinoma and squamous cell carcinoma of the lung: potential target for folate-linked therapeutic agents | Q38400924 | ||
| Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments | Q38524502 | ||
| Immune checkpoint inhibition in ovarian cancer | Q38800974 | ||
| Immune Checkpoint Therapy in Non-Small Cell Lung Cancer | Q38816823 | ||
| Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies | Q38816833 | ||
| Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression | Q38940035 | ||
| Involvement of Lyn and the atypical kinase SgK269/PEAK1 in a basal breast cancer signaling pathway | Q39200111 | ||
| Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro | Q39340367 | ||
| Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. | Q39408740 | ||
| Antitumor effects of a human dimeric antibody fragment 131I-AFRA-DFM5.3 in a mouse model for ovarian cancer | Q39446133 | ||
| Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity. | Q39543380 | ||
| Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung | Q39552028 | ||
| Breast cancers: MR imaging of folate-receptor expression with the folate-specific nanoparticle P1133. | Q39711656 | ||
| In vivo structural activity and optimization studies of folate-tubulysin conjugates | Q39821190 | ||
| Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor. | Q40059215 | ||
| Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells | Q40090882 | ||
| IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. | Q40091329 | ||
| Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells. | Q40101714 | ||
| Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate | Q40110187 | ||
| Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis | Q40127445 | ||
| Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma | Q40296292 | ||
| Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: a phase I study | Q40644063 | ||
| Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies | Q40646570 | ||
| Regression of Advanced Ovarian Carcinoma by Intraperitoneal Treatment With Autologous TLymphocytes Retargeted by a Bispecific Monoclonal Antibody | Q40678959 | ||
| Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing | Q41472501 | ||
| A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors | Q57975528 | ||
| Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: Clinical results in patients with minimal residual disease of ovarian cancer | Q60442191 | ||
| Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F(ab')2 fragments in ovarian carcinoma patients | Q72559537 | ||
| Development of a tumor-targeting MR contrast agent using the high-affinity folate receptor: work in progress | Q73364096 | ||
| Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study | Q74813455 | ||
| Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration | Q77501378 | ||
| Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival | Q78167058 | ||
| Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide | Q79998073 | ||
| Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-alpha for relapsed metastatic ovarian cancer | Q80233809 | ||
| Reducing Undesirable Hepatic Clearance of a Tumor-Targeted Vinca Alkaloid via Novel Saccharopeptidic Modifications | Q82067772 | ||
| The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer | Q84290611 | ||
| Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer | Q86328482 | ||
| PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer | Q86532062 | ||
| Degradation of BMS-753493, a novel epothilone folate conjugate anticancer agent | Q87412887 | ||
| Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer | Q34979610 | ||
| A step further in understanding the biology of the folate receptor in ovarian carcinoma. | Q35066040 | ||
| Membrane transport of folates | Q35173884 | ||
| Immunotherapy of folate receptor-expressing tumors: review of recent advances and future prospects. | Q35204546 | ||
| Folate receptor-α (FOLR1) expression and function in triple negative tumors | Q35225064 | ||
| Oncolytic virotherapy for ovarian cancer | Q35597082 | ||
| Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy | Q35749863 | ||
| Folate receptor endocytosis and trafficking | Q35749871 | ||
| Antifolates targeted specifically to the folate receptor | Q35749876 | ||
| Folate-receptor-targeted radionuclide imaging agents | Q35749885 | ||
| Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance | Q36050687 | ||
| High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation | Q36059727 | ||
| The glycophospholipid-linked folate receptor internalizes folate without entering the clathrin-coated pit endocytic pathway | Q36222686 | ||
| A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer | Q36299662 | ||
| Paradoxical impact of two folate receptors, FRα and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome. | Q36380927 | ||
| 6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors | Q36467564 | ||
| Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer | Q36508941 | ||
| Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor | Q36557169 | ||
| The folate receptor: what does it promise in tissue-targeted therapeutics? | Q36749423 | ||
| In vitro assembly of repertoires of antibody chains on the surface of phage by renaturation | Q36751560 | ||
| Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4. | Q36808757 | ||
| Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease | Q37052124 | ||
| Concordance of folate receptor-α expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients | Q37109499 | ||
| Early methyl donor deficiency may induce persistent brain defects by reducing Stat3 signaling targeted by miR-124 | Q37148242 | ||
| Folate receptor alpha as a tumor target in epithelial ovarian cancer | Q37254805 | ||
| Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945. | Q37479804 | ||
| The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity. | Q37586901 | ||
| IgE immunotherapy: a novel concept with promise for the treatment of cancer | Q37593712 | ||
| Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency. | Q37698945 | ||
| Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. | Q37964490 | ||
| EC145: a novel targeted agent for adenocarcinoma of the lung | Q37998528 | ||
| Anti-tumour strategies aiming to target tumour-associated macrophages. | Q38056746 | ||
| Folate and fetal programming: a play in epigenomics? | Q38087764 | ||
| Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging. | Q38204578 | ||
| P275 | copyright license | Creative Commons Attribution 2.5 Generic | Q18810333 |
| P433 | issue | 32 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | folic acid | Q127060 |
| neoplasm | Q1216998 | ||
| Folate receptor alpha | Q21107386 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 52553-52574 | |
| P577 | publication date | 2016-05-27 | |
| 2016-08-09 | |||
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Targeting folate receptor alpha for cancer treatment | |
| P478 | volume | 7 |
| Q92417504 | A Phenotypic Switch of Differentiated Glial Cells to Dedifferentiated Cells Is Regulated by Folate Receptor α |
| Q48104995 | Advances in ovarian cancer therapy |
| Q96219897 | An outlook on procedures of conjugating folate to (co)polymers and drugs for effective cancer targeting |
| Q57462222 | Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer |
| Q38720904 | Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling |
| Q90076309 | Bacteria increase host micronutrient availability: mechanisms revealed by studies in C. elegans |
| Q47283159 | Biomaterials-Based Approaches to Tumor Spheroid and Organoid Modeling. |
| Q41006050 | Biotinylated Chlorin and Its Zinc and Indium Complexes: Synthesis and In Vitro Biological Evaluation for Photodynamic Therapy |
| Q92736708 | Co-delivery of paclitaxel and curcumin to foliate positive cancer cells using Pluronic-coated iron oxide nanoparticles |
| Q104795121 | Combined and selective miR-21 silencing and doxorubicin delivery in cancer cells using tailored DNA nanostructures |
| Q49307169 | Combined use of EpCAM and FRα enables the high-efficiency capture of circulating tumor cells in non-small cell lung cancer |
| Q91776970 | Design of 5-fluorouracil (5-FU) loaded, folate conjugated peptide linked nanoparticles, a potential new drug carrier for selective targeting of tumor cells |
| Q90134243 | Development of oncolytic virotherapy: from genetic modification to combination therapy |
| Q95266929 | Dual Receptor-Targeted and Redox-Sensitive Polymeric Micelles Self-Assembled from a Folic Acid-Hyaluronic Acid-SS-Vitamin E Succinate Polymer for Precise Cancer Therapy |
| Q33918385 | Dual functionality nanobioconjugates targeting intracellular bacteria in cancer cells with enhanced antimicrobial activity. |
| Q64981084 | Enhancement of Binding Affinity of Folate to Its Receptor by Peptide Conjugation. |
| Q61798748 | Evaluation of Riboflavin Transporters as Targets for Drug Delivery and Theranostics |
| Q90171337 | Exploiting the folate receptor α in oncology |
| Q33914066 | Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma |
| Q55008640 | Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer. |
| Q38995020 | Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer. |
| Q49367303 | Folate receptor-α targeted near-infrared fluorescence imaging in high-risk endometrial cancer patients: a tissue microarray and clinical feasibility study |
| Q90185529 | Folate-appended cyclodextrin carrier targets ovarian cancer cells expressing the proton-coupled folate transporter |
| Q92110368 | Folic Acid Receptor-Mediated Targeting Enhances the Cytotoxicity, Efficacy, and Selectivity of Withania somnifera Leaf Extract: In vitro and in vivo Evidence |
| Q41207923 | Glycobiology of Eosinophilic Inflammation: Contributions of Siglecs, Glycans, and Other Glycan-Binding Proteins. |
| Q55061789 | Identification of a peptide for folate receptor alpha by phage display and its tumor targeting activity in ovary cancer xenograft. |
| Q93090675 | Modular Antigen-Specific T-cell Biofactories for Calibrated In Vivo Synthesis of Engineered Proteins |
| Q64080771 | Nanocomposites as biomolecules delivery agents in nanomedicine |
| Q33591671 | Next generation sequencing of extraskeletal myxoid chondrosarcoma |
| Q59134002 | One-Carbon Metabolism: Biological Players in Epithelial Ovarian Cancer |
| Q89186003 | Optimization Of Cancer Treatment Through Overcoming Drug Resistance |
| Q89171781 | Overexpression of folate receptor alpha is an independent prognostic factor for outcomes of pancreatic cancer patients |
| Q90233550 | PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy |
| Q90373455 | Peroxidase activities of gold nanowires synthesized by TMV as template and their application in detection of cancer cells |
| Q33900573 | Potent Therapeutic Activity Against Peritoneal Dissemination and Malignant Ascites by the Novel Anti-Folate Receptor Alpha Antibody KHK2805. |
| Q98164521 | Pre-clinical studies of EC2629, a highly potent folate- receptor-targeted DNA crosslinking agent |
| Q64075533 | Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies |
| Q91747824 | Radiation dosimetry of 18F-AzaFol: A first in-human use of a folate receptor PET tracer |
| Q98164567 | Radiopharmaceutical therapy in cancer: clinical advances and challenges |
| Q58735813 | Recent advances in "smart" delivery systems for extended drug release in cancer therapy |
| Q48151447 | Risk analysis of malignant potential of oral verrucous hyperplasia: A follow-up study of 269 patients and copy number variation analysis. |
| Q40089027 | Spheroid growth in ovarian cancer alters transcriptome responses for stress pathways and epigenetic responses. |
| Q92632099 | Targeted Nano-Drug Delivery of Colchicine against Colon Cancer Cells by Means of Mesoporous Silica Nanoparticles |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q37397674 | Therapeutic targets and new directions for antibodies developed for ovarian cancer. |
| Q92256212 | Ultrasensitive detection of circulating exosomes with a 3D-nanopatterned microfluidic chip |
| Q49931875 | Upconversion in photodynamic therapy: plumbing the depths |
Search more.